Arteaus Therapeutics sells royalty interest in Emgality for $260 mln [Reuters]
MS ASIA PACIFIC COMMON (APF)
US:NYSE Investor Relations:
asiapacificintl.com
Company Research
Source: Reuters
Arteaus Therapeutics sells royalty interest in Emgality for $260 mln - PE Hub Arteaus Therapeutics sells royalty interest in Emgality for $260 mln Print Email Atlas Venture OrbiMed Eli Lilly and Company’s Emgality Royalty Pharma Morgan Stanley Wilmer Cutler Pickering Hale and Dorr LLP Jones Day Maiwald PRESS RELEASE NEW YORK, /PRNewswire/ — Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million. Emgality was approved the U.S. Food and Drug Administration on September 27, 2018 and the European Medicines Agency on November 14, 2018. Emgality is an at-home, once monthly self-injection for the preventative treatment of episodic and chronic migraine in adults. “Having led the initial clini
Show less
Read more
Impact Snapshot
Event Time:
APF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APF alerts
High impacting MS ASIA PACIFIC COMMON news events
Weekly update
A roundup of the hottest topics